Endra Life Sciences ( (NDRA) ) has released its Q4 earnings. Here is a breakdown of the information Endra Life Sciences presented to its investors.
ENDRA Life Sciences Inc. is a company at the forefront of developing Thermo-Acoustic Enhanced UltraSound (TAEUS®) technology, primarily focusing on assessing liver fat content to aid in the diagnosis and management of liver-related metabolic diseases. This innovative approach addresses a significant gap in diagnostic tools for chronic liver conditions affecting millions globally.
In its latest earnings report, ENDRA Life Sciences shared its financial results for the fourth quarter and full year of 2024, alongside a business update. The company highlighted its strategic shift towards advancing the TAEUS Liver device through the FDA regulatory process and its new focus on using TAEUS as a biomarker solution for metabolic diseases.
Key financial metrics revealed that ENDRA reduced its cash burn significantly, with cash used in operations declining to $1.5 million in the fourth quarter of 2024 from $2.2 million in the same period the previous year. Despite an increase in operating expenses to $4.3 million due to non-cash charges, the company managed to implement cost-cutting measures effectively. The full-year net loss stood at $11.5 million, up from $10.1 million in 2023, primarily due to strategic inventory valuation adjustments.
Strategically, ENDRA has made substantial progress in refining its TAEUS Liver device, including initiating a multicenter pilot study and revising its regulatory strategy for a De Novo submission to the FDA. These efforts are aimed at enhancing the device’s accuracy and usability, with the ultimate goal of commercializing it for broader market applications.
Looking ahead, ENDRA Life Sciences remains focused on optimizing its TAEUS Liver device and advancing its regulatory submissions. The company is poised to continue its efforts in reducing operational costs while aligning its strategic initiatives with market opportunities, positioning itself for potential future growth in the medical technology sector.